A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

Trial Profile

A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2018

At a glance

  • Drugs Evofosfamide (Primary) ; Gemcitabine
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms MAESTRO
  • Sponsors EMD Serono; Merck KGaA; Merck Serono; Threshold Pharmaceuticals
  • Most Recent Events

    • 21 Jun 2018 According to a Caris Life Sciences media release, results were presented at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2018 (ESMO GI).
    • 21 Jun 2018 Results presented in a Caris Life Sciences media release.
    • 05 Jun 2018 Results assessing pharmacokinetics presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top